|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
47,361,000 |
Market
Cap: |
722.26(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$15.25 - $15.25 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Aerie Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of ophthalmic therapies for the treatment of patients with eye diseases and conditions including open-angle glaucoma, dry eye, and diabetic macular edema. Rhopressa® is a once-daily eye drop designed to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Rocklatan® is a once-daily fixed-dose combination of Rhopressa® and latanoprost, a prescribed drug for the treatment of patients with open-angle glaucoma or ocular hypertension. Co. is developing AR-15512, an ophthalmic solution for the treatment of patients with dry eye disease.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kopczynski Casey C. |
Chief Scientific Officer |
|
2019-02-23 |
4 |
D |
$40.04 |
$13,133 |
D/D |
(328) |
102,714 |
|
- |
|
Larocca John |
General Counsel |
|
2019-02-19 |
4 |
D |
$40.80 |
$62,914 |
D/D |
(1,542) |
23,458 |
|
- |
|
Mitro Thomas A |
President and COO |
|
2019-02-08 |
4 |
D |
$40.39 |
$50,124 |
D/D |
(1,241) |
63,016 |
|
- |
|
Rubino Richard J |
Chief Financial Officer |
|
2019-02-08 |
4 |
D |
$40.39 |
$41,844 |
D/D |
(1,036) |
326,762 |
|
- |
|
Kopczynski Casey C. |
Chief Scientific Officer |
|
2019-02-08 |
4 |
D |
$40.39 |
$28,313 |
D/D |
(701) |
103,042 |
|
- |
|
Anido Vicente Jr |
Chief Executive Officer |
|
2019-02-08 |
4 |
D |
$40.39 |
$65,593 |
D/D |
(1,624) |
150,109 |
|
- |
|
Mitro Thomas A |
President and COO |
|
2019-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
12,778 |
64,257 |
|
- |
|
Rubino Richard J |
Chief Financial Officer |
|
2019-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
10,667 |
327,798 |
|
- |
|
Kopczynski Casey C. |
Chief Scientific Officer |
|
2019-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
103,743 |
|
- |
|
Anido Vicente Jr |
Chief Executive Officer |
|
2019-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
25,413 |
151,733 |
|
- |
|
Larocca John |
General Counsel |
|
2019-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
7,000 |
25,000 |
|
- |
|
Kopczynski Casey C. |
Chief Scientific Officer |
|
2019-02-01 |
4 |
AS |
$46.03 |
$507,844 |
D/D |
(11,000) |
95,743 |
|
- |
|
Kopczynski Casey C. |
Chief Scientific Officer |
|
2019-01-02 |
4 |
AS |
$35.21 |
$387,313 |
D/D |
(11,000) |
106,743 |
|
- |
|
Kopczynski Casey C. |
Chief Scientific Officer |
|
2018-12-03 |
4 |
AS |
$39.79 |
$437,894 |
D/D |
(11,000) |
117,743 |
|
- |
|
Cagle Gerald D. |
Director |
|
2018-11-16 |
4 |
B |
$41.75 |
$83,493 |
D/D |
2,000 |
19,800 |
2.39 |
- |
|
Kopczynski Casey C. |
Chief Scientific Officer |
|
2018-11-01 |
4 |
AS |
$52.99 |
$592,521 |
D/D |
(11,000) |
128,743 |
|
- |
|
Kopczynski Casey C. |
Chief Scientific Officer |
|
2018-10-01 |
4 |
AS |
$60.43 |
$666,204 |
D/D |
(11,000) |
136,517 |
|
- |
|
Rubino Richard J |
Chief Financial Officer |
|
2018-09-27 |
4 |
AS |
$60.36 |
$1,002,386 |
D/D |
(16,605) |
317,131 |
|
- |
|
Rubino Richard J |
Chief Financial Officer |
|
2018-09-26 |
4 |
AS |
$60.18 |
$3,009,445 |
D/D |
(50,000) |
333,736 |
|
- |
|
Rubino Richard J |
Chief Financial Officer |
|
2018-09-14 |
4 |
AS |
$60.00 |
$120 |
D/D |
(2) |
383,736 |
|
- |
|
Rubino Richard J |
Chief Financial Officer |
|
2018-09-13 |
4 |
S |
$60.17 |
$2,076,608 |
D/D |
(34,512) |
383,738 |
|
- |
|
Kopczynski Casey C. |
Chief Scientific Officer |
|
2018-09-04 |
4 |
S |
$60.00 |
$661,024 |
D/D |
(11,000) |
147,517 |
|
- |
|
Mitro Thomas A |
President and COO |
|
2018-08-27 |
4 |
AS |
$60.27 |
$11,451,006 |
D/D |
(190,000) |
51,479 |
|
- |
|
Mitro Thomas A |
President and COO |
|
2018-08-27 |
4 |
OE |
$3.15 |
$598,500 |
D/D |
190,000 |
241,479 |
|
- |
|
Kopczynski Casey C. |
Chief Scientific Officer |
|
2018-08-01 |
4 |
S |
$68.00 |
$751,298 |
D/D |
(11,000) |
158,517 |
|
- |
|
333 Records found
|
|
Page 8 of 14 |
|
|